The antibiotic-resistant infections treatment market is estimated to be worth USD 4,377.4 million in 2024 and is projected to reach a value of USD 7,637.5 million by 2034, expanding at a CAGR of 5.7% over the assessment period of 2024 to 2034
Antibiotic-resistant infections also referred to as antimicrobial-resistant infections, result when microorganisms develop a defence mechanism against the action of any drugs that originally worked to kill & control them. As such, the infections are hard to treat, and one is most likely to pass on the diseases.
The global burden of antibiotic drug resistance has a significant impact on public health, antibacterial drug manufacturers, academic & research institutes, and treating severe illness, which has increased the overall mortality rate. As per the WHO antimicrobial resistance briefing, overall 4.95 million deaths are associated with bacterial AMR in which 25.7% of cases are directly related to bacterial AMR.
| Attributes | Description |
|---|---|
| Estimated Global Antibiotic-Resistant Infections Treatment Market Size (2024E) | USD 4,377.4 million |
| Projected Global Antibiotic-Resistant Infections Treatment Market Value (2034F) | USD 7,637.5 million |
| Value-based CAGR (2024 to 2034) | 5.7% |
Antibiotic resistance results from various factors such as the overuse and misuse of antibiotics in human beings, poor infection control, bad sanitary conditions, and globalization in trade and travel. When bacteria are exposed to antibiotics, susceptible bacteria are killed, leaving the resistant ones to survive and proliferate. Such natural selection is accelerated in the presence of overseen or poorly used antibiotics.
Added to this is the fact that most chronic condition patients often need hospitalization, surgical operations, or long-term care-all these exposing them greatly to the bacteria of health facilities. For example, an article published by MDPI in June 2020 stated that patients who acquire infections at the hospital have more than 5 times higher chances of antibiotic resistance compared to patients with community-acquired infections.
Several studies that have looked into this area of application of personalized medicine in treating antibiotic-resistant infections, such as urinary tract infections and wound infections, have resulted in findings showing that it may reduce the risk of antimicrobial resistance by prescribing different antibiotics based on a patient's history of personal infection.
The purpose of the personalized treatment approach in antibiotic-resistant infection treatment is to prescribe the specific, narrow-spectrum antibiotic that is the most effective for the particular strain and severity of infection experienced by the patient, rather than prescribing broad-spectrum antibiotics, the mass use significantly increases the chances of antibiotic resistance in the disease-causing pathogen species.
This coupled with a growing trend in the prevalence rate of hospital-acquired antibiotic-resistant infections, which makes the need for drugs and antibiotics that can treat antibiotic-resistant infections.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing Incidence of Chronic Diseases Resulting in Infections Worldwide Fostering Market Growth
The incidence of chronic diseases is increasing in this present world. Some of these chronic diseases, like diabetes mellitus, neurological diseases, and chronic indwelling catheterization, are in themselves a form of immunocompromised making it impossible for the human system to fight an infection.
Possibilities are quite high that in the presence of such chronic conditions, a complicated infection may trap these people, and they might grow resistant to antibiotics.
Chronic disease patients are usually administered antibiotics to treat several infections repetitively this in turn gives the bacteria causing the infection the chance to develop resistance against such antibiotics. According to a BioMed Central Ltd. paper in February 2024, independent chronic co-morbidities like diabetes mellitus were associated with about a 4-fold higher risk of antibiotic resistance.
Introduction of Personalized Treatment Options Provides an Opportunity for Market Players
Precision antibiotic prescribing and antimicrobial optimization strategies that propagate the introduction of personalized treatment options in the cases of antibiotic-resistant infections will drive this further. This is very promising and is one of the options that can be used in the fight against antimicrobial resistance and improvement of treatment outcomes for patients with antibiotic-resistant infections.
The idea of personalized medicine, for the complexity involved in using the approach of 'one dose fits all,' implies the potential use of human individual variability in an antimicrobial therapy approach. Herein, the characteristics of the individual patient are to be considered for the personalization of treatment regimens and optimization of drug exposure and efficacy according to tolerance.
Overview of Restrictive Factors for the Antibiotic-Resistant Infections Treatment Market
Obtaining regulatory approval for medicines is often an obstacle, with difficulties noted in bureaucracy, differences in the clinical trial requirements of different countries, and changes in the regulatory landscape.
Changes in FDA standards for clinical trial design over the past two decades have made antibiotic trials particularly challenging. The complexity and high cost of phase 3 clinical trials can exceed the financial means of small companies that have stepped in to fill the antibiotic development gap left by large pharmaceutical companies. This deviates the company’s focus and does not allow it to further investigate and launch its product in the market, limiting its growth.
Global antibiotic-resistant infections treatment sales increased at a CAGR of 4.0% from 2019 to 2023. For the next ten years (2024 to 2034), projections are that expenditure on antibiotic-resistant infection treatment will rise at 5.7% CAGR. There is always the risk of acquiring antibiotic-resistant infections in a hospital setting due to rising infection rates and overuse of antibiotics as a treatment modality.
This further leads to increased risks of infection transmission between two different patients within the same hospital setting because of insufficient infection control practices, which occur due to poor hand hygiene, poor sterilization and disinfection methods, and failure in introducing a proper system for the use of medical devices across hospitals.
It is estimated that, for example, in a National Library of Medicine article dated February 2023, the pooled prevalence for HAIs in Southeast Asia was 21.6 percent, whereas during the same period, hospitals alone in Indonesia accounted for the highest single-country rate for HAIs.
Over the past few years, antibiotic resistance has been recognized as a key threat to global health; hence, the one health approach encourages a coordinated response by focusing on the health. These entail development of new antibiotics, improvement of infection controls, and assurance of the proper use of antibiotics through management.
Principal Consultant
Tier 1 companies, which dominate the antibiotic-resistant infections treatment market, have revenue of more than USD 100 million and constitute 39.7% of the world market, so they have quite a large share of this market. These big corporations are recognized for their wide-reaching manufacturing capability and range of offerings.
These companies provide a range of services such as recycling, manufacturing, reconditioning that are guided by up to date technology so as to meet the specifications set by law and produce products of high quality. Top brands in its sector are Pfizer Inc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Merck & Co., Inc., Glaxosmithkline Plc (GSK), F.Hoffmann-La Roche Ltd. among others.
Tier 2 companies are those gaining between USD 50M and USD 100M revenue yearly. These firms target areas where they have considerable influence as they account for 28.4% market share. They are renowned for their strength abroad and intimate acquaintance with local markets. Some well-known tier 2 companies include AbbVie, AstraZeneca, Bayer AG, Teva Pharmaceutical Industries Ltd., Sanofi, Sandoz AG, and Lupin Ltd.
Tier 3 consists mostly of small companies that operate locally and serve specific markets. These companies typically make less than USD 50 million in revenue. They focus on meeting the needs of their local markets and do not have a large reach like bigger companies. Tier 3 is considered unorganized because these companies are not as structured or formalized as larger, organized competitors.
| Countries | Value CAGR |
|---|---|
| United States | 3.3% |
| Germany | 2.7% |
| United Kingdom | 2.3% |
| China | 6.8% |
| India | 6.3% |
The United States industry will dominate the global market with the 85.5% market share in 2024 and is projected to continue experiencing high growth throughout the forecast period.
The United States holds the leading market share for antibiotic-resistant infection treatments because it possesses several risk factors that increase the likelihood of pneumonia. This includes undernutrition, air pollution, smoke, overcrowding, and other infectious diseases in the United States. The possibility of having pneumonia becomes greater for such people.
For instance, in the journal article by the American Thoracic Society in 2022, it is estimated that nearly 1 million adults in the United States are annually admitted to the hospital for pneumonia.
China's growth in the antibiotic-resistant infections treatment market is very commendable, followed by surging demand through biotechnological advancement and academic and research institutes. The region’s robust investment in research and development, coupled with the rapidly growing healthcare sector, accelerated the demand for antibiotic-resistant infection treatment.
In addition, the China’s government has been supportive of treating antibiotic-resistant infections because of the diversity of medical applications in which its potential is realized.
The highly developed pharmaceutical industry provides the ideal setting in India for developing and producing new antibiotics and other alternative treatments. It is envisioned that investment in research and development, with huge efforts in discovering novel antibiotics and adjunct therapies, would offset the crisis of resistance.
Development and deployment of rapid diagnostic tools can improve the accuracy of infection diagnosis and hence prescription of antibiotics only where necessary. This can help to curb the main misuses of antibiotics and slow down the spread of resistance.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Segment | Nitrofurans (Nitrofurantoin) (Drug Class) |
|---|---|
| Value Share (2024) | 22.7% |
Nitrofurans (Nitrofurantoin) is going to dominate the global market with a 22.7% market share in 2024 and are projected to continue experiencing high growth throughout the forecast period.
Nitrofurantoin is mainly used to treat and prevent UTIs, which top the list of most common infections worldwide. Comparatively, nitrofurantoin has continued to show very low rates of resistance compared to other antibiotics, making it a very reliable drug in the treatment of uncomplicated UTIs.
Different mechanisms have been outlined for the action of nitrofurantoin, generally centered on the inhibition of vital bacterial enzymes involved in DNA, RNA, and cell wall synthesis. The multifaceted attack on the bacterium prevents it from developing resistance.
| Segment | Oral (Route of Administration) |
|---|---|
| Value Share (2024) | 63.2% |
Oral antibiotics, compared with intravenous ones, are much more convenient for patients. They can take them at home, which increases adherence in patients and reduces the need for hospitalization. Such convenience is important in ensuring good adherence to the prescribed antibiotic regimen, an important factor in treating infections effectively and preventing further development of resistance.
| Segment | Cystitis (Disease Indication) |
|---|---|
| Value Share (2024) | 61.5% |
The cystitis segment will dominate the global market with a 61.5% market share in 2024 and is projected to continue experiencing high growth throughout the forecast period.
Cystitis is popularly known as a urinary tract infection, being one of the most common bacterial infections and occurring more frequently in the female gender. High incidence and recurrence are what drive the profound effect of cystitis on people's demand for effective treatments. Several patients experience recurrences, resulting in frequent use of antibiotics, entailing the ensuing high risk of encountering antibiotic-resistant strains.
| Segment | Adult (Age Group) |
|---|---|
| Value Share (2024) | 45.9% |
Adults are more likely to have chronic underlying conditions such as diabetes, heart disease, and cancer, all of which may put individuals at risk through immune compromise and consequently affect their vulnerability to infection, including infections from resistant bacteria. Notably, many of these chronic conditions require medical devices, especially catheters and ventilators, which could become sources of infection.
| Segment | Retail Pharmacies (Distribution Channel) |
|---|---|
| Value Share (2024) | 41.9% |
The retail pharmacy setting is usually the most common or direct first point of contact between the healthcare providers and the patients. Pharmacists could play a vital role in educating patients regarding proper antibiotic use, adhering to prescribed dosages, and even cautioning against some of the disadvantages of antibiotic resistance.
Such direct interaction would prove helpful in keeping watch over patient compliance and advice as and when required to facilitate effective treatment.
The antibiotic-resistant infections treatment market is characterized by the presence of big established players such as Pfizer Inc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.) and Merck & Co., Inc. These market players are deploying different strategies to secure large market share and increase their revenue.
Popular strategies adopted by the key players are collaborations and partnerships. Companies are investing in developing more innovative products and establishing partnerships with various stakeholders such as distributors, healthcare professionals etc. Acquisitions and recognition are a priority for leading antibiotic-resistant infection treatment manufacturers as they work to create new product lines and expand their global consumer base. For instance.
As per drug class, the market has been categorized into penicillin and combinations, (piperacillin and tazobactam, pivmecillinam, Ticarcillin/Clavulanate, amoxicillin and Clavulanate potassium), cephalosporin, Colistin, carbapenems, (meropenem and imipenem), fluoroquinolones, aminoglycoside antibiotics, amikacin, gentamicin, (Nitrofurans (nitrofurantoin), Fosfomycin) among others.
This segment is further categorized into oral and parenteral.
This disease indication segment is bifurcated into pyelonephritis or cUTI, cystitis, pneumonia among other disease indications.
This age group segment is bifurcated into pediatric, adult, and geriatric.
Different distribution channels include hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online drug stores.
Industry analysis has been carried out in key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa.
The global market was valued at around USD 4,154.3 million in 2023.
The market is set to reach a valuation of around USD 7,637.5 million by the end of 2034.
The Nitrofurans (nitrofurantoin) segment, within the drug class segment, held a 22.8% share of the global antibiotic-resistant infections treatment market in 2023.
Demand for the global market increased at a 4.0% CAGR from 2019 to 2023.
The global market is estimated to be around USD 4,377.4 million by 2024.
The United States antibiotic-resistant infections treatment industry accounted for around 23.3% share of the global market in 2023.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Drug Class 5.2. By Route of Administration 5.3. By Disease Indication 5.4. By Age Group 5.5. By Distribution Channel 5.6. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class 6.1. Penicillin and Combinations 6.1.1. Piperacillin and Tazobactam 6.1.2. Pivmecillinam 6.1.3. Ticarcillin/Clavulanate 6.1.4. Amoxicillin and Clavulanate Potassium 6.2. Cephalosporin 6.3. Colistin 6.4. Carbapenems 6.4.1. Meropenem 6.4.2. Imipenem 6.5. Fluoroquinolones 6.6. Aminoglycoside Antibiotics 6.6.1. Amikacin 6.6.2. Gentamicin 6.7. Nirtofurans (Nitrofurantoin) 6.8. Fosfomycin 6.9. Others 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration 7.1. Oral 7.2. Parenteral 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Disease Indication 8.1. Pyelonephritis or cUTI 8.2. Cystitis 8.3. Pneumonia 8.4. Other Disease Indication 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Age Group 9.1. Pediatric 9.2. Adult 9.3. Geriatric 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel 10.1. Hospital Pharmacies 10.2. Gynecology and Urology Clinics 10.3. Drug Stores 10.4. Retail Pharmacies 10.5. Online Drug Stores 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 11.1. North America 11.2. Latin America 11.3. East Asia 11.4. South Asia and Pacific 11.5. Western Europe 11.6. Eastern Europe 11.7. Middle East and Africa 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 19. Sales Forecast 2024 to 2034 by Drug Class, Route of Administration, Disease Indication, Age Group and Distribution Channel for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 21. Company Profile 21.1. Pfizer Inc. 21.2. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) 21.3. Merck & Co., Inc. 21.4. Glaxosmithkline Plc (GSK) 21.5. F.Hoffmann-La Roche Ltd. 21.6. AbbVie 21.7. AstraZeneca 21.8. Bayer AG 21.9. Teva Pharmaceutical Industries Ltd. 21.10. Sanofi 21.11. Sandoz AG 21.12. Lupin Ltd. 21.13. Advacare Pharma 21.14. Validus Pharmaceuticals LLC
Healthcare
June 2023
REP-GB-13025
273 pages
Explore Healthcare Insights
View Reports
Antibiotic-Resistant Infections Treatment Market
